Figure 1.
Reverse phase (RP)-HPLC analysis of the chemoselectivity of compounds 1-4 in recombinant WT-TTR vs K15A-TTR homotetramer solutions and human plasma. (a) C18-RP-HPLC analysis of WT-TTR (top) or K15A-TTR (bottom) pre-incubated (18 h) with candidate covalent kinetic stabilizer 4 (analogous data for 1-3 are described in Supplementary Fig. 1). (b) Rate of WT-TTR–(stilbene)n conjugate formation analyzed by C18-RP-HPLC. Samples were analyzed in triplicate and the error bars represent standard deviations. (c) C18-RP-HPLC assessment of the modification of TTR in human blood plasma by compounds 3 and 4 (analogous data for 1 and 2 are shown in Supplementary Fig. 8).
